Yuhan Corporation - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Yuhan Corporation - Product Pipeline Review - 2016', provides an overview of the Yuhan Corporation's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Yuhan Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Yuhan Corporation - The report provides overview of Yuhan Corporation including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Yuhan Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Yuhan Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Yuhan Corporation's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Yuhan Corporation - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Yuhan Corporation's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Yuhan Corporation Snapshot 6 Yuhan Corporation Overview 6 Key Information 6 Key Facts 6 Yuhan Corporation - Research and Development Overview 7 Key Therapeutic Areas 7 Yuhan Corporation - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Yuhan Corporation - Pipeline Products Glance 15 Yuhan Corporation - Late Stage Pipeline Products 15 Phase III Products/Combination Treatment Modalities 15 Yuhan Corporation - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Yuhan Corporation - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Yuhan Corporation - Drug Profiles 19 (metformin hydrochloride SR + rosuvastatin calcium) 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 bilastine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 YH-12852 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 YH-14618 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 (amlodipine maleate + chlorthalidone + telmisartan) 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 YH-22189 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 YH-1177 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 YH-14619 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 YH-18406 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 YH-18420 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 YH-24931 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 YH-25348 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 YH-25448 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 YH-25723 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 YH-BIO 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 YH-GKA 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 YH-NCE2 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 YH-NCE3 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 YH-NCE4 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 YH-siRNA1 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 YH-siRNA2 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 YH-siRNA3 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Yuhan Corporation - Pipeline Analysis 43 Yuhan Corporation - Pipeline Products by Target 43 Yuhan Corporation - Pipeline Products by Route of Administration 45 Yuhan Corporation - Pipeline Products by Molecule Type 46 Yuhan Corporation - Pipeline Products by Mechanism of Action 47 Yuhan Corporation - Recent Pipeline Updates 48 Yuhan Corporation - Dormant Projects 49 Yuhan Corporation - Company Statement 50 Yuhan Corporation - Locations And Subsidiaries 51 Head Office 51 Other Locations & Subsidiaries 51 Yuhan Corporation - Key Manufacturing Facilities 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54
List of Tables
Yuhan Corporation, Key Information 6 Yuhan Corporation, Key Facts 6 Yuhan Corporation - Pipeline by Indication, 2016 8 Yuhan Corporation - Pipeline by Stage of Development, 2016 10 Yuhan Corporation - Monotherapy Products in Pipeline, 2016 11 Yuhan Corporation - Combination Treatment Modalities in Pipeline, 2016 12 Yuhan Corporation - Partnered Products in Pipeline, 2016 13 Yuhan Corporation - Partnered Products/ Combination Treatment Modalities, 2016 14 Yuhan Corporation - Phase III, 2016 15 Yuhan Corporation - Phase II, 2016 16 Yuhan Corporation - Phase I, 2016 17 Yuhan Corporation - Preclinical, 2016 18 Yuhan Corporation - Pipeline by Target, 2016 44 Yuhan Corporation - Pipeline by Route of Administration, 2016 45 Yuhan Corporation - Pipeline by Molecule Type, 2016 46 Yuhan Corporation - Pipeline Products by Mechanism of Action, 2016 47 Yuhan Corporation - Recent Pipeline Updates, 2016 48 Yuhan Corporation - Dormant Developmental Projects,2016 49 Yuhan Corporation, Other Locations 51 Yuhan Corporation, Subsidiaries 51 Yuhan Corporation, Key Manufacturing Facilities 52
List of Figures
Yuhan Corporation - Pipeline by Top 10 Indication, 2016 8 Yuhan Corporation - Pipeline by Stage of Development, 2016 10 Yuhan Corporation - Monotherapy Products in Pipeline, 2016 11 Yuhan Corporation - Combination Treatment Modalities in Pipeline, 2016 12 Yuhan Corporation - Partnered Products in Pipeline, 2016 13 Yuhan Corporation - Pipeline by Top 10 Target, 2016 43 Yuhan Corporation - Pipeline by Route of Administration, 2016 45 Yuhan Corporation - Pipeline by Molecule Type, 2016 46 Yuhan Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016 47
Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. EvolvRead More...
Global heat transfer fluids market size is likely to be valued at USD 3.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing demand for for heat recovery management in industries such as metal processing, pharmaceuticaRead More...
Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving creamRead More...
Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to driveRead More...
Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population iRead More...
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.